Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04513678 · ClinicalTrials.gov registry record · NA
Development of ImmunOncoTool
A NA study, sponsored by Northwestern University.
- Completed
- Registry status
- NA
- Development phase
- 64
- Enrollment target
NCT04513678 is a NA study that has completed, run by Northwestern University. The registered enrollment target is 64 participants.
The verdict
NCT04513678, a NA study, has completed, sponsored by Northwestern University.
- COMPLETED
- Registry status
- NA
- Development phase
- 64 participants
- Enrollment target
Study Summary
The purpose of this study is to facilitate the recognition and early management of Immune Related Adverse Events (irAEs) experienced by cancer patients taking immunotherapy. This is done through the development of a web-based platform in which patients receive valuable education about irAEs, patients' irAEs are routinely monitored, patient reported irAEs are embedded into patient clinical care, and patient-provider communication and prompt management of irAEs is facilitated. The intervention component includes access to the web-based platform, routine monitoring of irAEs every week for twelve weeks and then bi-weekly for an additional eight weeks, and messages to healthcare providers and patients if a reported irAE is deemed severe enough that it warrants provider attention. Participants are randomized into either an intervention group (described above) or a control group, in which their irAEs are monitored once after a twelve week interval and again after an additional eight weeks. Additionally, both intervention and control participants complete three assessments: baseline (at the beginning of the research study), 12-week follow-up, and 20-week follow-up.
Interventions
- BEHAVIORAL ImmunOncoTool Condition
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2019-12-18 |
| Est. Completion | 2021-12-17 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04513678
The ClinicalTrials.gov registry entry for NCT04513678 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ImmunOncoTool Condition is the first listed.
NCT04513678 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04513678 about?
NCT04513678 is a clinical study titled "Development of ImmunOncoTool". The purpose of this study is to facilitate the recognition and early management of Immune Related Adverse Events (irAEs) experienced by cancer patients taking immunotherapy. This is done through the development of a web-based platform in which patients receive valuable education about irAEs, patient...
What is the current status of trial NCT04513678?
This trial is currently completed. It is a NA study. The enrollment target is 64 participants. The study started on 2019-12-18. Estimated completion is 2021-12-17.
What interventions are being tested in trial NCT04513678?
The interventions under investigation include: ImmunOncoTool Condition (BEHAVIORAL).
Who is sponsoring clinical trial NCT04513678?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.